Compare Enbridge Inc (ENB) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enbridge Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? Enbridge Inc trades at $47.52 (market cap $105.42B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Enbridge Inc is far larger — about 14× Spyre Therapeutics Inc. Common Stock's market cap, and Enbridge Inc pays a 5.9% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enbridge Inc for 92 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| ENB | SYRE | |
|---|---|---|
Market Cap | $105.42B | $7.52B |
Volume | 3,621,007 | 1,441,031 |
Sector | Energy | Health |
52-Week High | $58.04 | $108.92 |
52-Week Low | $45.23 | $22.18 |
Typical Hold Time | 92 Days | 0 Days |
Enterprise Value | $187.30B | $6.52B |
Dividend Yield | 5.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Enbridge (ENB) trades at $47.35, up 0.85% today, with mixed technical signals showing bearish moving averages but neutral oscillators. The company demonstrates strong fundamentals with three consecutive quarterly earnings beats and a 6% dividend yield. Revenue grew to $65.19 billion in 2025 with net income of $7.49 billion, though 2026 projections show margin compression. Recent news highlights ENB's expansion into European renewables and Permian Basin acquisitions as growth drivers.
ENB offers income investors a stable 6% yield with growth potential from its $41 billion project backlog, but faces headwinds from rising interest rates and potential oil price volatility. Analyst consensus is balanced with 48% buy ratings and a $61.63 price target suggesting 30% upside, though technical indicators remain cautious near-term.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enbridge Inc
Enbridge owns extensive midstream assets that transport hydrocarbons across the U.S. and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. Finally, the firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.
Read more on ENB →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
